Study of Rivoglitazone in Type 2 Diabetes Mellitus

Summary

This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period.

Timeline

Start

2007-04-23

Primary completion

2009-02-12

Completion

2009-02-12

Drugs

Indications